Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo + AVD
nivolumab with doxorubicin, vinblastine and dacarbazine · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults and adolescents age 12 or older with untreated stage III or IV classical Hodgkin lymphoma.
SUPPORTING DATA
Evidence behind the decision
- Study
- SWOG 1826 randomized 994 patients age 12 or older to nivolumab plus AVD or brentuximab vedotin plus AVD.
- Key result
- The progression-free survival hazard ratio was 0.42 (95% CI, 0.27–0.67) at 13.7 months median follow-up. The median was unreached in both groups.
- Safety to report
- In the nivolumab arm, 39% had serious adverse reactions and 9% had immune-mediated reactions.
- Evidence limits
- This trial supports the front-line combination. The same FDA notice covers separate traditional approvals for later-line monotherapy.
LAMPGEN ANALYSIS
Why it matters
This adds checkpoint blockade to front-line chemotherapy for advanced classical Hodgkin lymphoma, with randomized evidence that included adolescents.
What research teams should watch
Coordinate pediatric and adult workflows for immune toxicity, infection surveillance and growth factor prophylaxis. Keep first-line treatment separate from the simultaneous later-line conversions.
PRIMARY RECORDS